References
- Van de Kerkhof P. C. Consistent control of psoriasis by continuous long‐term therapy: The promise of biological treatments. J Eur Acad Dermatol Venereol 2006; 20: 639–50
- Psoriasis, P. C Van de Kerkhof. Mosby, St Louis, MO 2003
- Hradil E., Lindstrom C., Moller H. Intermittent treatment of psoriasis with clobetasol propionate. Acta Derm Venereol 1978; 58: 375–7
- Gottlieb A. B., Ford R. O., Spellman M. C. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque‐type psoriasis of nonscalp regions. J Cutan Med Surg 2003; 7: 185–92
- Beutner K., Chakrabarty A., Lemke S., Yu K. An intra‐individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. J Drugs Dermatol 2006; 5: 357–60
- Katz H. I., Hien N. T., Prawer S. E., Scott J. C., Grivna E. M. Betamethasone dipropionate in optimized vehicle. Intermittent pulse dosing for extended maintenance treatment of psoriasis. Arch Dermatol 1987; 123: 1308–11
- Melian E. B., Spencer C. M., Jarvis B. Clobetasol propionate foam, 0.05%. Am J Clin Dermatol 2001; 2: 89–92, discussion 93
- Jarratt M. T., Clark S. D., Savin R. C., Swinyer L. J., Safley C. F., Brodell R. T., Yu K. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque‐type psoriasis. Cutis 2006; 78: 348–54
- Menter A. Topical monotherapy with clobetasol propionate spray 0.05% in the cobra trial. Cutis 2007; 80((5 suppl))12–19
- Feldman S. R., Housman T. S. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol 2003; 4: 221–4
- Housman T. S., Mellen B. G., Rapp S. R., Fleischer A. B., Jr., Feldman S. R. Patients with psoriasis prefer solution and foam vehicles: A quantitative assessment of vehicle preference. Cutis 2002; 70: 327–32
- Ali S. M., Brodell R. T., Balkrishnan R., Feldman S. R. Poor adherence to treatments: A fundamental principle of dermatology. Arch Dermatol 2007; 143: 912–15
- Baldwin H. E. Tricks for improving compliance with acne therapy. Dermatol Ther 2006; 19: 224–36
- Lee I. A., Maibach H. I. Pharmionics in dermatology: A review of topical medication adherence. Am J Clin Dermatol 2006; 7: 231–6
- Wauters O., Roland I., De la Brassinne M. [Corticosteroids and their vehicle in the treatment of scalp psoriasis.]. Rev Med Liege 2007; 62: 196–9
- Feldman S. R., Gelfand J. M., Stein Gold L., Jones S. D. The role of topical therapy for patients with extensive psoriasis. Cutis 2007; 79((1 suppl 2))18–31
- Opmeer B. C., Heydendael V. M., Deborgie C. A., Spuls P. I., Bossuyt P. M., Bos J. D., de Rie M. A. Patients with moderate‐to‐severe plaque psoriasis preferred oral therapies to phototherapies: A preference assessment based on clinical scenarios with trade‐off questions. J Clin Epidemiol 2007; 60: 696–703
- Warino L., Balkrishnan R., Feldman S. R. Clobetasol propionate for psoriasis: Are ointments really more potent?. J Drugs Dermatol 2006; 5: 527–32
- Hongbo Y., Thomas C. L., Harrison M. A., Salek M. S., Finlay A. Y. Translating the science of quality of life into practice: What do dermatology life quality index scores mean?. J Invest Dermatol 2005; 125: 659–64